

1648#3

DOCKET NO.: UPN-4099/
G-1154

COPY OF PAPERS
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

JUL 11 2002

TECH CENTER 1600/2900

In Re Application of:

David B. Weiner, et al.

Serial No.: 09/935,100

Filing Date: August 22, 2001

For: VPR FUNCTION AND ACTIVITY



Group Art Unit: 1648

Examiner: Not Yet Assigned

DATE OF DEPOSIT: June 27 2002
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON
THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, DC 20231.

Gwilym John Owen Attwell
TYPED NAME: Gwilym John Owen Attwell
REGISTRATION NO.: 45,449

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- ☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:

☐ Certification in Accordance with §1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in §1.17(p) is attached.

- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with §1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in §1.17(p) is attached.

- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
EXCEPT THAT:

☒ In view of the voluminous nature of references 45 and 47, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.


- ☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:
- ☒ Copies of references 1-61 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 08/167,608, filed December 15, 1993.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: June 27, 2002


Gwilym John Owen Attwell
Registration No. 45,449

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

JUL 11 2002

TECH CENTER 1600/2900

Sheet 1 of 7

Form PTO-1449 Modified		Docket No. UPN-4099/G-1154	Serial No. 09/935,100
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date August 22, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
1	Adachi, et al., "Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone", <i>J of Virology</i> , 1986, 59, 284-291		
2	Aguanno, et al., "12-O-Tetradecanoylphorbol-13-Acetate-induced differentiation of a human rhabdomyosarcoma cell line" <i>Cancer Research</i> , 50:3377-3382		
3	Arya, et al., "Trans-activator gene of human t-lymphotropic virus type III (HTLV-III)", <i>Science</i> , 1985, 229, 69-73		
4	Chantal Petit, et al., "Human immunodeficiency virus infection down regulates HLA class II expression and induces differentiation in promonocytic U937 cells", <i>J. Clin. Invest.</i> , 1987, 79:1883-1889		
5	Cohen, et al., "Identification of HIV-1 vpr product and function", <i>J. Acquir. Immune Defic. Syndr.</i> , 1990, 3, 11-18		
6	Cohen, et al., "Human immunodeficiency virus vpr product is a virion-associated regulatory protein," <i>J. Virol.</i> , 1990, 64, 3097-3099		
7	Colmenares, et al., <i>Cell</i> , 1989		
8	Dedera, et al., "Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells," <i>J. of Virol.</i> , 1989, 63, 3205-3208		
9	Fisher, et al., "A molecular clone of HTLV-III with biological activity," <i>Nature</i> , 1985, 316,262-265		
10	Gallo, et al., "Frequent detection and isolation of cytopathic retroviruses(HTLV-III) from patients with aids and at risk for aids," <i>Science</i> , 1984, 224, 500-503		
EXAMINER		DATE CONSIDERED	

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900 Sheet 2 of 7

Form PTO-1449 Modified		Docket No. UPN-4099/G-1154	Serial No. 09/935,100
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date August 22, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
11	Garrett, et al., "Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products," <i>J. of Virology</i> , 65, 1653-1657		
12	Gras-Masse, et al., "A synthetic protein corresponding to the entire vpr gene product from the human immunodeficiency virus HIV-1 is recognized by antibodies from HIV-infected patients," <i>Int. J. Peptide Protein Res.</i> , 1990, 36, 219-226		
13	Griffin, et al., "Activation of HIV gene expression during monocyte differentiation by induction of NF-KB," <i>Nature</i> , 1989, 339, 70-73		
14	Harada, et al., "Tumor promoter, TPA, Enhances replication of HTLV-III/LAV," <i>Virology</i> , 1986, 154, 249-258		
15	Hattori, et al., "The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages," <i>Proc. Natl. Acad. Sci. USA</i> , 1990, 87, 8080-8084		
16	Hiti, et al., <i>Mol. Cell. Biol.</i> , 1989, 9, 4722-4730		
17	Kozak, M., "Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes," <i>Cell</i> , 1986, 44, 283-292		
18	A. Voller, et al., <i>Immunoassays for the 80's.</i> , University Park, 1981		
19	Levy, et al., "Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS," <i>Science</i> , 1984, 225, 840-842		
20	Levy, D.N., et al., "Induction of cell differentiation by HIV-1 VPR," <i>Aids Res. Human Retroviruses</i> , 1994, 10(S1), S92, No. XP 002031073 (Abstract only)		
21	Levy, et al., "Induction of cell differentiation by human immunodeficiency virus 1 vpr," <i>Cell</i> , 1993, 72, 541-550		
EXAMINER		DATE CONSIDERED	

* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

JUL 11 2002

Form PTO-1449 Modified		Docket No. UPN-4099/G-1154		Serial No. 09/935,100	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner, et al.			
U.S. Department of Commerce Patent and Trademark Office		Filing Date August 22, 2001		Group Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	22	Li, et al., "Human immunodeficiency virus type 1 DNA synthesis, integration and efficient viral replication in growth-arrested T cells," <i>J. Virol.</i> 1993 , 67, 3969-3977			
	23	Ling, et al., <i>PCR Meth Appl.</i> , 1991 , 1, 63-69			
	24	Morgenstern, et al., <i>Nucl. Acids. Res.</i> , 1990 , 18, 3587-3596			
	25	Myers, et al., <i>Aids Res. Hum. Retrovir.</i> , 1992 , 8, 373			
	26	Ogawa, et al., "mutational analysis of the human immunodeficiency virus vpr open reading frame," <i>J. Virol.</i> 1989 , 63, 4110-4114			
	27	Ratner, et al., <i>Science</i> , 1985 , 313, 277-284			
	28	Ratner, et al., <i>AIDS Res. Hum. Retroviruses</i> , 1987 , 3, 57-69			
	29	Reiss, et al., "antibody response to viral proteins U (vpu) and R (vpr) in HIV-1 infected individuals," <i>J. Acquired Immune Deficiency Syndromes</i> , 1990 , 3, 115-122			
	30	Reiz, et al., <i>AIDS Res. Human Retro.</i> , 1992 , 8, 1549			
	31	Rich et al., "Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1)," <i>J. Clin. Invest.</i> 1992 , 89, 176-183			
EXAMINER			DATE CONSIDERED		

COPY OF PAPERS
ORIGINALLY FILED

Sheet 4 of 7

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. UPN-4099/G-1154	Serial No. 09/935,100
Applicant David B. Weiner, et al.		Filing Date August 22, 2001	
Group Not Yet Assigned		TECH CENTER 1600/2900	

O I P E
 JUL 0 5 2002
 PATENT & TRADEMARK OFFICE

RECEIVED
 JUL 11 2002
 TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
32		Rose, et al., "Frequent identification of HIV-1 Dna in bronchoalveolar lavage cells obtained from individuals with the acquired immunodeficiency syndrome, <i>Am. Rev. Respir. Dis.</i> , 1986, 143, 850-854		
33		Roulston, et al., "Induction of monocytic differentiation and NF-kB-like activities by human immunodeficiency virus 1 infection of myelomonblastic cells," <i>J. Exp. Med.</i> 1992, 175, 751-763		
34		Salahuddin, et al., <i>Blood</i> , 1986, 68, 281		
35		Schuitemaker, et al., "Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocyctotropic to T-cell-tropic virus populations," <i>J. Virol.</i> 1992, 66, 1354-1360		
36		Shibata, et al., <i>J. Med. Primatol.</i> , 1990, 19, 217-225		
37		Shibata, et al., "Mutational analysis of the human immunodeficiency virus type 2 (HIV-2) genome in relation to HIV-1 and simian immunodeficiency virus SIV agm," <i>J. Virol.</i> 1990, 64, 742-747		
38		Siegel, et al., <i>Dev. Brain Res.</i> , 1988, 44, 269-280		
39		Starcich, et al., "Characterization of long terminal repeat sequences of HTLV-III," <i>Science</i> , 1985, 227, 538-540		
40		Stratton, et al., <i>Carcinogenesis</i> , 1989, 10, 899-905		
41		Valentin, et al., <i>J. Aids</i> , 1991, 4, 751		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">EXAMINER</td> <td style="width: 50%; border: none;">DATE CONSIDERED</td> </tr> </table>			EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED			



COPY OF PAPERS
ORIGINALLY FILED

Sheet 5 of 7

Form PTO-1449 Modified		Docket No. UPN-4099/G-1154	Serial No. 09/935,100
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date August 22, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	42	Weiner, et al., <i>Pathobiology</i> , 1991, 59, 361-371	
	43	Weiner, et al., <i>Oncogene</i> , 1989, 4, 1175-1183	
	44	Westervelt, et al., "Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants," <i>J. Virol.</i> 1992, 66, 3925-3931	
*	45	Wide, <i>Radioimmune Assay Method</i> , Kirkham, Ed., E. & S. Livingstone, Edinburgh, 1970, pp 199-206	
	46	Wong-Staal, et al., <i>Aids Res. Hum. Retroviruses</i> , 1987, 3, 33-39	
*	47	Work, T.S. et al., <i>Laboratory Techniques and Biochemistry in Molecular Biology</i> , 1978, North Holland Publishing Company, N.Y.	
	48	Yu, et al., "Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein," <i>J. Virol.</i> 1990, 64, 5688-5693	
	49	Yuan, et al., <i>Aids Res. Hum. Retroviruses</i> , 1990, 6, 1265-1271	
	50	Zack, et al., "HIV-1 production from infected peripheral blood T cells after HTLV-1 induced mitogenic stimulation," <i>Science</i> , 1988, 240, 1026-1029	
	51	Janel, et al., "Localization of the vpr gene product in SIVMAC infected cells," <i>Int'l Conference on AIDS</i> , 1989, 5, 523, Abstract T.C.O. 45.	
EXAMINER		DATE CONSIDERED	

* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

Form PTO-1449 Modified		Docket No. EPN-4099/G-1154	Serial No. 09/935,100
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant David B. Weiner, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date August 22, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
52	Refaili, et al., "recombinant HIV-1 vpr protein induces cellular differentiation in vitro," <i>J of Cellular Biochemistry</i> , Supplement 18B, 140 Abstract J 262		
53	Miller, <i>Bio Essays</i> , 1989, 11, 91-95		
54	Luckow, et al., <i>Bio Technol</i> , 1988, 6, 47-55		
55	Harlow, et al., <i>Cold Spring Harbor Laboratory, N.Y.</i> 1988, 73 and 124		
56	European Patent Office Supplementary European Search Report, dated November 5, 1997, 6 pages		
57	Hattori, N. et al., "The vpr Gene of HIV-2 is a Transactivator Necessary for viral Expression in Primary Macrophages", <i>Aids Res. Human Retroviruses</i> , 1991, 7(2), 177, No. XP 002031072 (Abstract only)		
58	Levy, D.N. et al., "HIV Regulatory Gene Function Analysis in a Rhabdomyosarcoma Cell Line", <i>Vaccines. Modern Approaches to New Vaccines Including Prevention of Aids</i> , Tenth Annual Meeting, Cold Spring Harbor, New York, September, 1992, 243-249, No. XP 000673175		
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified						
Docket No. UPN-4099/G-1154						Serial No. 09/935,108
List of Patent and Publication Cited by Applicant (Use several sheets if necessary)						Applicant David B. Weiner, et al.
U.S. Department of Commerce Patent and Trademark Office						Filing Date August 22, 2001
						Group Not Yet Assigned
RECEIVED JUL 11 2002 TECH CENTER 1600/200						
U. S. PATENT DOCUMENTS						
Examiner Initial		Document No.	Date	Name	Class	Subclass
	59	4,808,536	02/28/89	Chang, et al.,	435	5
	60	5,001,230	03/19/91	Braun, et al.	536	27
FOREIGN PATENT DOCUMENTS						
Examiner Initial		Document No.	Date	Country	Translation YES NO	
	61	WO 90/15875	12/27/90	PCT		
EXAMINER				DATE CONSIDERED		